Additional file 1 of Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
Creators: name: Deodhar, Atul A.
name: Mease, Philip J.
name: Rahman, Proton
name: Navarro-Compán, Victoria
name: Strand, Vibeke
name: Hunter, Theresa
name: Bolce, Rebecca
name: Leon, Luis
name: Lauzon, Steve
name: Marzo-Ortega, Helena
Publisher: name: figshare
Year: 2021
Subjects: subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Physiology
subject: Pharmacology
subject: Biotechnology
subject: Ecology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: 111714 Mental Health
subject: FOS: Health sciences

description: Additional file 1: Table S1. Changes from baseline in patient reported outcomes at week 52. Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection at week 0. Data shown as mean (SD) at baseline, and mBOCF (SD) at week 52. ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying anti-rheumatic drugs; IXE = ixekizumab; JSEQ = Jenkins Sleep Evaluation Questionnaire; mBOCF = modified baseline observation carried forward; N = number of patients in the analysis population; n = number of patients in each treatment subgroup; NRS = numeric rating scale; PtGA = patient global disease activity; Q = question; Q2W = every 2 weeks; Q4W = every 4 weeks; SD = standard deviation; TNFi = tumor necrosis factor inhibitor. Figure S1. Association between ASAS response and improvements in ASAS PROs for ixekizumab Q2W-treated patients after 52 weeks. Q2W ixekizumab-treated patients. § p&lt;0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p&lt;0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p&lt;0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = (ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying antirheumatic drugs; LSM = least squares mean; mBOCF = modified baseline observation carried forward; Nx = number of observations; PROs = patient-reported outcomes; PtGA = patient global disease activity; Q = question; Q2W = every 2 weeks; SE: standard error; TNFi = tumor necrosis factor inhibitor. Figure S2. Association between ASAS response and improvements in ASAS PROs for ixekizumab Q4W-treated patients after 52 weeks. Q4W ixekizumab-treated patients. § p&lt;0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p&lt;0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p&lt;0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = (ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying antirheumatic drugs; LSM = least squares mean; mBOCF = modified baseline observation carried forward; Nx = number of observations; PROs = patient reported outcomes; PtGA = patient global disease activity; Q = question; Q4W = every 4 weeks; SE = standard error; TNFi = tumor necrosis factor inhibitor. Figure S3. Association between ASAS response and improvements in other PROs for ixekizumab Q2W-treated patients after 52 weeks.Q2W ixekizumab-treated patients. § p&lt;0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p&lt;0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p&lt;0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = (ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; bDMARD = biologic disease-modifying antirheumatic drugs; JSEQ = Jenkins Sleep Evaluation Questionnaire; LSM = least squares mean; mBOCF: modified baseline observation carried forward; NRS = numeric rating scale; Nx = number of observations; PROs = patient reported outcomes; Q = question; Q2W = every 2 weeks; SE = standard error; TNFi = tumor necrosis factor inhibitor. Figure S4. Association between ASAS response and improvements in other PROs for ixekizumab Q4W-treated patients after 52 weeks.Q4W ixekizumab-treated patients. § p&lt;0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; * p&lt;0.0001, ASAS40 achieved vs. ASAS20 not achieved; † p&lt;0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA. Values are LSM improvements from baseline (SE). mBOCF was used for imputation of missing data. Fold difference = ASAS40 responder/ASAS20 non-responder) -1, or (ASAS40 responder/ASAS20 but not ASAS40 responder) -1. ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; bDMARD = biologic disease-modifying antirheumatic drugs; JSEQ = Jenkins Sleep Evaluation Questionnaire; LSM = least squares mean; mBOCF = modified baseline observation carried forward; NRS = numeric rating scale; Nx = number of observations; PROs = patient-reported outcomes; Q = question; Q4W = every 4 weeks; SE = standard error; TNFi = tumor necrosis factor inhibitor.